Switch theme
Sign up to access all valuation multiples
Diagonal Bio AB is developing a diagnostic platform for ultra-rapid, parallel, accurate and cost-efficient detection of any kind of pathogen - Panviral.
2020
8
LTM Revenue n/a
LTM EBITDA n/a
$1.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diagonal Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Diagonal Bio achieved revenue of $2K and an EBITDA of -$1.2M.
Diagonal Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diagonal Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $21K | $2K | XXX | XXX | XXX |
| Gross Profit | -$9K | $0.2M | XXX | XXX | XXX |
| Gross Margin | -42% | 8930% | XXX | XXX | XXX |
| EBITDA | -$1.6M | -$1.2M | XXX | XXX | XXX |
| EBITDA Margin | -7469% | -49865% | XXX | XXX | XXX |
| Net Profit | -$1.2M | -$1.7M | XXX | XXX | XXX |
| Net Margin | -5745% | -70278% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, Diagonal Bio's stock price is SEK 0 (or $0).
Diagonal Bio has current market cap of SEK 15.8M (or $1.6M), and EV of SEK 14.1M (or $1.4M).
See Diagonal Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4M | $1.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, Diagonal Bio has market cap of $1.6M and EV of $1.4M.
Diagonal Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Diagonal Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Diagonal Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.4M | XXX | XXX | XXX |
| EV/Revenue | 611.5x | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | XXX | XXX |
| P/E | -1.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiagonal Bio's NTM/LTM revenue growth is n/a
Diagonal Bio's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged n/a for the same period.
Over next 12 months, Diagonal Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Diagonal Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Diagonal Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -89% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | -24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0K | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 639% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diagonal Bio acquired XXX companies to date.
Last acquisition by Diagonal Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Diagonal Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Diagonal Bio founded? | Diagonal Bio was founded in 2020. |
| Where is Diagonal Bio headquartered? | Diagonal Bio is headquartered in Sweden. |
| How many employees does Diagonal Bio have? | As of today, Diagonal Bio has 8 employees. |
| Is Diagonal Bio publicy listed? | Yes, Diagonal Bio is a public company listed on NGM. |
| What is the stock symbol of Diagonal Bio? | Diagonal Bio trades under DIABIO ticker. |
| When did Diagonal Bio go public? | Diagonal Bio went public in 2025. |
| Who are competitors of Diagonal Bio? | Similar companies to Diagonal Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Diagonal Bio? | Diagonal Bio's current market cap is $1.6M |
| What is the current revenue growth of Diagonal Bio? | Diagonal Bio revenue growth between 2023 and 2024 was -89%. |
| Is Diagonal Bio profitable? | Yes, Diagonal Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
